Papalocal
Loading…
News
← All news
Health

FDA-approved mRNA flu vaccine arrives for adults 50+, outperforming standard shots by 27%

Moderna's mFLUSIVA — the first flu vaccine built on mRNA technology — is rolling out to pharmacies now, but insurance coverage gaps and a paralyzed federal advisory panel could complicate who actually gets it.

How does this story make you feel?

For the first time, Americans 50 and older can get a flu shot built on the same mRNA technology that powered COVID-19 vaccines — and a large clinical trial shows it works meaningfully better than the standard dose. The catch: a paralyzed federal advisory panel, unresolved insurance questions, and spotty pharmacy availability mean the vaccine's arrival is more complicated than a simple upgrade.

The FDA approved Moderna's mFLUSIVA for adults ages 50 to 64 and granted accelerated approval for those 65 and older ahead of the coming respiratory virus season. The accelerated approval for the older group reflects an ongoing requirement: Moderna must complete an additional study comparing mFLUSIVA against the high-dose flu shots already recommended for people 65 and older, according to AARP and MedPage Today.

The pivotal data come from the Fluent phase 3 trial, which enrolled 40,703 adults 50 and older — mean age 64, 57% women — and randomly assigned them to receive either the trivalent mRNA-1010 vaccine or a licensed standard-dose comparator. RT-PCR-confirmed influenza A or B illness occurred in 2% of mRNA-1010 recipients versus 2.8% of standard-vaccine recipients, a relative vaccine efficacy of 26.6% (95% CI 16.7–35.4), meeting criteria for both noninferiority and superiority, according to results published in the New England Journal of Medicine.

Among the more than 19,000 participants ages 65 and older — the group most vulnerable to severe flu — relative vaccine efficacy was 27.4% (95% CI 12.1–40.0), which the researchers said suggests benefits comparable to enhanced vaccines such as high-dose or adjuvanted shots already used in that age group, according to MedPage Today. For hospitalizations, emergency department visits, and urgent care encounters combined, the mRNA vaccine showed 47.9% greater relative efficacy than standard-dose comparators.

The mRNA vaccine works almost 30% better than the traditional vaccine in the elderly. It will protect them from seasonal flu, but they will also start to generate immunity against other parts of the flu virus that don't change.— Dr. Deborah Fuller, professor of microbiology, UW School of Medicine

Fuller explained that the mRNA vaccine can produce antibodies recognizing a broader range of influenza viruses and also trains certain white blood cells to provide an additional layer of immune protection — a feature she said is especially valuable for older adults, whose immune systems respond less robustly to vaccines with age, a process she called 'immunosenescence.'

Beyond this season, experts say the mRNA platform carries longer-term advantages. Traditional flu vaccines take five to six months to manufacture using chicken eggs — a process that can introduce mutations reducing effectiveness — while mRNA vaccines can be produced in under two months, according to Johns Hopkins professor Gigi Gronvall, quoted by AARP. That shorter timeline means manufacturers can start production closer to the actual flu season, reducing the risk of a mismatch between the vaccine and circulating strains.

That's the longer-term hope with these mRNA vaccines. You wouldn't have such a bad mismatch, like we saw the last two years.— Dr. Helen Chu, allergy and infectious disease professor, UW Medicine

The mismatch concern is not abstract. Last season, a new influenza A subclade known as K emerged and proved resistant to the prior year's vaccine. Washington state recorded more than 250 flu deaths last season; the season before was the state's deadliest in over a decade, with more than 500 deaths. Of those deaths, over 91% were in people 50 and older, according to KOMO News.

The new vaccine does carry a higher side-effect burden than traditional flu shots. In the Fluent trial, injection-site pain was reported by 65.8% of mRNA-1010 recipients versus 29.8% of standard-vaccine recipients; fatigue by 45.1% versus 20.3%; headache by 37.8% versus 18.0%; and muscle aches by 35.4% versus 11.6%, according to MedPage Today. Most reactions were mild to moderate and transient. Serious adverse events were infrequent and similar between groups — 2.2% in the mRNA group versus 1.9% in the comparator group. No cases of acute myocarditis, myopericarditis, or pericarditis occurred in the mRNA group within 42 days of vaccination.

Fuller said anyone over 50 who had a severe reaction to a COVID-19 mRNA vaccine should consult their doctor or pharmacist before getting mFLUSIVA. But she was direct about the overall calculus.

Having a vaccine is better than not having a vaccine. And mRNA vaccines are safe. They are effective.— Dr. Deborah Fuller, professor of microbiology, UW School of Medicine

Whether patients can afford the new shot is a separate and unresolved question. Adults 65 and older should be able to get mFLUSIVA covered under at least some Medicare plans, according to the Seattle Times. Most private insurers will likely cover it for adults 50 and older, according to AHIP, a national health insurer trade group. But Medicaid coverage is uncertain, and Washington's Office of the Insurance Commissioner said it does not yet know which insurers will cover the vaccine for people ages 50 to 64, according to the Seattle Times. Without insurance, the vaccine costs about $171 per dose, according to the Centers for Medicare and Medicaid Services.

The coverage uncertainty traces directly to a disruption at the federal level. The Advisory Committee on Immunization Practices — the CDC expert panel that typically recommends which FDA-approved vaccines insurers must cover — has not met this year. Health Secretary Robert F. Kennedy Jr. fired all 17 members last summer and replaced them with picks who, according to the Seattle Times, had little to no experience running vaccine clinical trials or analyzing results. The American Academy of Pediatrics sued, and a federal judge found in a March preliminary ruling that Kennedy's moves were likely illegal. The federal government has appealed. The panel's next scheduled meeting is in October, though its previous two meetings this year were canceled due to the litigation.

There is no ACIP.— Dr. Helen Chu, allergy and infectious disease professor, UW Medicine

Chu noted that without an ACIP recommendation, Medicaid may not cover mFLUSIVA. She and other experts emphasized that traditional flu vaccines remain widely available and recommended that people get whatever vaccine they can access, since all offer some protection against severe disease.

mFLUSIVA is being rolled out to pharmacies including CVS and Walgreens, though not every local pharmacy is expected to carry it immediately, according to KOMO News. Only 29.2% of eligible Washingtonians received a flu vaccine last season, according to the state Department of Health.

Why it matters — Adults 50 and older — the group most likely to be hospitalized or die from flu — now have access to a more effective vaccine, but a federal policy breakdown over the vaccine advisory panel is creating real uncertainty about who will be able to afford it.

⚠ Not yet confirmed

  • Most private insurers will likely cover mFLUSIVA for adults 50 and older
  • Pfizer's quadrivalent mRNA flu vaccine showed 34.5% greater relative efficacy versus standard inactivated quadrivalent flu vaccine in adults 18–64

Sources differ on How much better mFLUSIVA is than standard-dose flu shots: Almost 30% better / 26.6% relative efficacy (trial result) (newsroom.uw.edu / medpagetoday.com) vs About 25% better in people 50 and over (aarp.org)

Reported by komonews.com, newsroom.uw.edu, nejm.org, medpagetoday.com, aarp.org, seattletimes.com

People in this story
  • Robert F. Kennedy Jr.
    26th United States Secretary of Health and Human Services since 2025
  • Johns Hopkins
    American entrepreneur, philanthropist, and abolitionist (1795–1873)

Community

Be the first to comment.

Share this story
Text Email